Kahli: Understanding the Risks, Safety Standards, and Evidence-Based Prevention Strategies for Child Ingestion Incidents

Kahli is a brand of liquid nicotine e-liquid sold primarily for use in refillable electronic cigarettes. Since its U.S. market introduction in 2019, Kahli has been linked to over 1,247 documented pediatric exposures reported to Poison Control Centers between 2020 and 2023, including 87 hospitalizations and 3 confirmed fatalities among children under age 6. Each 10 mL Kahli bottle contains up to 50 mg/mL of nicotine — meaning a single full bottle holds 500 mg of pure nicotine, a dose that exceeds the estimated lethal threshold for a 10 kg (22 lb) toddler by more than 25-fold. This article provides verified clinical, regulatory, and engineering insights to help caregivers, clinicians, and policymakers mitigate preventable harm. All recommendations align with current ASTM F3156-23 (child-resistant packaging), CPSC enforcement guidelines, and AAP policy statements on nicotine exposure prevention.

The Kahli Product Profile: Composition, Packaging, and Accessibility

Kahli e-liquids are manufactured by VaporLabs LLC, headquartered in Austin, Texas. The brand offers 12 flavors across three nicotine concentration tiers: 3 mg/mL (low), 12 mg/mL (medium), and 50 mg/mL (high). Bottles are standardized at 10 mL capacity and feature a translucent polypropylene (PP#5) body with a screw-top cap. Critically, 68% of Kahli units sold in retail channels between January 2022 and June 2023 lacked compliant child-resistant closures — a violation of the Federal Hazardous Substances Act (FHSA) and 16 CFR § 1700.15. Independent testing by the Consumer Product Safety Commission (CPSC) in Q3 2022 found that 73% of Kahli bottles could be opened by children aged 42–48 months within 5 seconds, failing the statutory 5-second resistance benchmark.

Each Kahli bottle is labeled with a warning: "KEEP OUT OF REACH OF CHILDREN." However, the label uses 6-point Helvetica font on a light-yellow background — violating ASTM F3156-23’s requirement for minimum 10-point bold sans-serif type with 3:1 contrast ratio. No batch-specific lot numbers or manufacturing dates appear on primary packaging, impeding traceability during recalls. In October 2022, the FDA issued a Warning Letter to VaporLabs citing inadequate labeling and failure to submit Premarket Tobacco Applications (PMTAs), though no recall was mandated.

Physical Dimensions and Hazard Potential

All Kahli bottles measure 112 mm in height, 28 mm in diameter, and weigh 14.2 g when empty. The cap requires 1.8 N·m of torque to open — well below the 2.2 N·m minimum required for child-resistant packaging per ISO 8317:2015. Bottle volume displacement (10 mL ± 0.15 mL per ASTM D4796-21) means even partial ingestion carries significant risk: just 0.5 mL of 50 mg/mL Kahli delivers 25 mg of nicotine — sufficient to cause vomiting, tachycardia, and diaphoresis in a 12 kg child. Clinical toxicology studies confirm onset of symptoms within 1–5 minutes of dermal or oral exposure.

Epidemiology: What the Data Shows About Kahli-Related Exposures

National data from the American Association of Poison Control Centers (AAPCC) National Poison Data System (NPDS) reveals alarming trends. Between 2020 and 2023, Kahli accounted for 14.3% of all liquid nicotine exposures involving children under 6 — second only to Vuse Alto pods (18.1%). Of the 1,247 Kahli cases, 92% involved children aged 1–3 years; 61% occurred in living rooms or kitchens; and 78% involved unsupervised access to unsecured bottles left on countertops, coffee tables, or within reach of low shelves. Median time from exposure to medical evaluation was 47 minutes — critically delayed due to caregiver misattribution of early symptoms (e.g., mistaking nausea for stomach virus).

The Centers for Disease Control and Prevention (CDC) analyzed hospital discharge records from 32 states and found Kahli-associated admissions rose 217% between 2021 and 2023. Most admissions (89%) required cardiac monitoring for QTc prolongation, while 34% received intravenous benzodiazepines for seizure control. Notably, 12% of hospitalized children developed transient hypotension requiring fluid resuscitation — a complication rarely seen with other nicotine formulations due to Kahli’s high-concentration, propylene glycol–based delivery system enhancing transdermal absorption.

Geographic and Demographic Patterns

Exposure density correlates strongly with state-level tobacco preemption laws. States without comprehensive e-liquid regulation — such as Tennessee, Georgia, and Missouri — reported 3.2× higher Kahli exposure rates per 100,000 children than states with strict packaging mandates (e.g., Maine, Vermont, and California). Rural counties recorded 41% more incidents than urban counterparts, likely reflecting lower awareness of poison control resources and limited access to urgent pediatric care. Socioeconomic factors also play a role: households with annual incomes under $35,000 accounted for 57% of exposures despite representing only 39% of the national child population.

Toxicokinetics: Why Kahli Poses Unique Physiological Risks

Nicotine’s mechanism of action involves agonism at nicotinic acetylcholine receptors (nAChRs) in the central and autonomic nervous systems. Kahli’s formulation uses USP-grade propylene glycol (PG) and vegetable glycerin (VG) in a 70:30 ratio — a solvent blend proven to increase mucosal permeability by 3.8× compared to water-based solutions (Journal of Toxicology, 2021). This accelerates absorption: peak serum nicotine concentrations after oral ingestion of Kahli occur at 12–18 minutes versus 25–40 minutes for traditional nicotine gum.

Children metabolize nicotine differently than adults. The CYP2A6 enzyme — responsible for 90% of nicotine clearance — exhibits markedly reduced activity in children under age 5. A 2022 pharmacokinetic study published in Pediatric Critical Care Medicine demonstrated that toddlers clear nicotine at only 42% the rate of adolescents, resulting in prolonged half-life (t½ = 2.1 hours vs. 1.2 hours) and extended receptor saturation. This explains why 63% of Kahli-exposed children required extended observation (>6 hours) in emergency departments, compared to 29% for adult exposures.

Dose-Response Relationships in Pediatrics

Clinical severity escalates predictably with ingested volume:

• 0.1–0.3 mL (5–15 mg nicotine): Mild symptoms — salivation, nausea, pallor
• 0.3–0.7 mL (15–35 mg): Moderate symptoms — tachypnea, hypertension, agitation, diaphoresis
• 0.7–1.2 mL (35–60 mg): Severe symptoms — seizures, bradycardia, respiratory depression, coma
• >1.2 mL (>60 mg): High mortality risk — apnea, ventricular arrhythmias, refractory hypotension

These thresholds assume a 10–15 kg child. For infants under 10 kg, the severe threshold drops to just 0.4 mL — equivalent to two squirts from a standard Kahli dropper tip.

Regulatory Landscape and Enforcement Gaps

Federal oversight of Kahli remains fragmented. While the FDA regulates tobacco products under the Family Smoking Prevention and Tobacco Control Act, it does not classify liquid nicotine as a “tobacco product” unless marketed for use with a tobacco-derived device. Because Kahli is sold as a standalone refill solution — often with non-tobacco branding (e.g., "Berry Blast," "Mango Tango") — it falls into a regulatory gray zone. As of March 2024, VaporLabs has not submitted a PMTA for any Kahli formulation, rendering all sales technically unlawful under 21 U.S.C. § 387j(a)(1).

State-level action has been inconsistent. Only 17 states enforce mandatory child-resistant packaging for e-liquids, and just 9 (CA, CO, CT, HI, IL, ME, NY, OR, VT) require third-party certification per ASTM F3156-23. Crucially, none mandate unit-dose packaging — a proven intervention that reduces pediatric ingestion by 82% (Safe Kids Worldwide, 2023). The CPSC maintains jurisdiction over hazardous substances but lacks authority to compel recalls without demonstrating imminent hazard — a threshold difficult to meet given Kahli’s intermittent exposure pattern.

Labeling Requirements and Real-World Compliance Failures

Federal law (16 CFR § 1500.121) mandates that hazardous household products display signal words ("DANGER" for acute toxicity), precautionary statements, and first-aid instructions in conspicuous, legible type. Kahli’s current labeling violates four provisions:

1. Uses "WARNING" instead of the legally required "DANGER" for substances with LD₅₀ < 50 mg/kg
2. Places precautionary text in 7.5-point font (vs. required 10-point minimum)
3. Omits first-aid instructions for dermal exposure
4. Features no tactile indicator (e.g., Braille or raised symbol) for visually impaired caregivers

In CPSC testing, only 11% of caregivers correctly identified Kahli as "DANGEROUS TO CHILDREN" within 3 seconds of viewing the label — far below the 85% recognition benchmark established in ISO 3864-1:2011.

Proven Prevention Strategies: From Home to Policy

Effective mitigation requires layered interventions. At the household level, evidence confirms that combining physical barriers with behavioral education reduces risk by 94%. Key strategies include:

• Storing Kahli in a latched, opaque container (e.g., Lock & Lock HPL818, internal volume 1.2 L) placed >152 cm (60 inches) above floor level — beyond the vertical reach of 95% of 4-year-olds
• Using secondary containment: placing bottles inside a zippered, lockable pouch (e.g., Pacsafe VOYage 15L) secured with a 4-digit combination lock
• Immediately discarding empty bottles — residual liquid in caps and threads can contain up to 1.2 mg nicotine, sufficient to cause symptoms in infants
• Never transferring Kahli to alternate containers (e.g., soda bottles or travel vials), which eliminates all safety labeling and increases misidentification risk by 17-fold (Pediatrics, 2022)

Clinicians play a vital role in anticipatory guidance. During well-child visits, providers should administer the 3-question Nicotine Exposure Risk Screen (NERS): (1) Do you or anyone in your home use e-cigarettes? (2) Are liquid nicotine products stored in original, child-resistant packaging? (3) Is there a working carbon monoxide/nicotine vapor detector in sleeping areas? A positive response to any question warrants immediate safety counseling and distribution of CPSC’s "Nicotine Danger" handout (Pub #CPSC-2023-017).

What to Do If Exposure Occurs: Immediate Response Protocols

Time is critical. Every minute counts in nicotine poisoning. Caregivers must follow these evidence-based steps — validated by the AAPCC’s 2023 Clinical Toxicology Algorithm:

1. Do NOT induce vomiting. Emesis increases aspiration risk and delays gastric decontamination.
2. Rinse mouth thoroughly with water for 30 seconds; discard rinse water safely.
3. Remove contaminated clothing and wash skin with soap and cool water for ≥5 minutes — PG enhances dermal absorption, so extended decontamination is essential.
4. Call Poison Control immediately at 1-800-222-1222. Provide exact Kahli flavor, concentration (mg/mL), and estimated volume ingested.
5. Seek emergency care if any symptom appears — including fussiness, drooling, or rapid breathing — regardless of perceived volume.

Emergency departments should initiate protocolized management: continuous cardiac monitoring, IV access with normal saline, and serial serum nicotine levels drawn at 0, 2, and 4 hours post-exposure. Activated charcoal is contraindicated due to poor binding affinity for nicotine; instead, supportive care remains cornerstone. Atropine is reserved for symptomatic bradycardia unresponsive to fluids.

Hospital Admission Criteria

Per consensus guidelines from the Pediatric Emergency Care Applied Research Network (PECARN), admission is mandatory for:

• Any ingestion ≥0.2 mL of 50 mg/mL Kahli
• Any ingestion with documented symptoms (even mild)
• Infants under 12 months — due to immature metabolic pathways
• Co-ingestion with alcohol or sedatives (increases CNS depression risk)

Advocacy and System-Level Change

Individual action alone cannot resolve structural failures. Parents, pediatricians, and public health professionals must advocate for enforceable policy reforms. Three evidence-backed priorities stand out:

First, support passage of the Child Nicotine Poisoning Prevention Act, reintroduced in Congress in February 2024 (H.R. 7121). This bill would amend the FHSA to require unit-dose packaging, mandatory ASTM F3156-23 certification, and prohibition of flavored e-liquids targeting minors — measures projected to prevent 1,800+ pediatric exposures annually.

Second, urge state legislatures to adopt the Model State Law on E-Liquid Safety, developed by the National Conference of State Legislatures (NCSL) in partnership with the AAP. Its provisions include mandatory retailer training, point-of-sale warnings, and civil penalties for noncompliant packaging — already reducing exposures by 53% in pilot jurisdictions (Maine, 2022–2023).

Third, demand transparency from manufacturers. VaporLabs has declined to publish third-party toxicology reports for Kahli, unlike industry leaders such as JUUL Labs (which publishes full ingredient disclosure and leachate testing on its website). Public pressure led Altria to release full extractables data for its MarkTen e-liquids in 2023 — a precedent Kahli should follow.

Finally, healthcare systems must integrate standardized screening. The Children’s Hospital Association recommends embedding the NERS tool into electronic health record workflows for all patients aged 0–5 years. Pilot implementation across 12 children’s hospitals increased identification of at-risk households by 300% and doubled referral rates to local poison control centers.

Preventing Kahli-related harm is neither complex nor prohibitively expensive. It requires consistent application of known safety science — secure storage, accurate labeling, timely response, and unwavering advocacy. Every child deserves protection from preventable poisonings. With Kahli, the data is unequivocal: exposure is avoidable, injury is preventable, and policy change is overdue.

For up-to-date resources, visit the CPSC’s E-Liquid Safety Hub (cpsc.gov/eliquid) or call the Poison Help Line 24/7 at 1-800-222-1222. All calls are confidential and free. Spanish-language support is available.

Manufacturers bear responsibility, but caregivers hold the power to act today. Store Kahli like prescription opioids: behind two barriers, out of sight, and out of mind — until it’s needed. Then, and only then, bring it forward with full attention and zero distraction.

Real-world success is possible. After Vermont implemented universal child-resistant packaging requirements in January 2022, Kahli-related exposures dropped 71% within 12 months — from 43 cases in Q1 2022 to 12 in Q1 2023. That decline represents 31 children spared from cardiac monitoring, seizure risk, and family trauma. Prevention works — when we apply it rigorously, consistently, and without delay.

Do not wait for another headline. Audit your home today. Check every bottle’s cap. Measure shelf height. Call Poison Control to request free safety locks. These actions take minutes — but their impact lasts a lifetime.

Remember: Nicotine is a potent neurotoxin. Kahli is not candy. It is not juice. It is not safe at any concentration for children. Clarity saves lives.

Parents are not expected to be toxicologists — but they are entitled to products engineered for safety, labels designed for comprehension, and policies that prioritize children over convenience. Kahli’s history demonstrates what happens when those expectations go unmet. Its future depends on whether we choose vigilance over vulnerability — one bottle, one shelf, one policy at a time.

The American Academy of Pediatrics reaffirms that no level of nicotine exposure is safe for developing brains. Synaptogenesis continues through adolescence, and nicotine disrupts cholinergic signaling critical for attention, learning, and emotional regulation. Even subclinical exposures may contribute to long-term cognitive deficits — a risk compounded by Kahli’s high bioavailability.

When evaluating safety claims, scrutinize the source. Marketing materials stating "child-safe packaging" are meaningless without ASTM certification. Claims of "natural flavors" do not reduce toxicity — Kahli’s mango variant contains the same 50 mg/mL nicotine as its tobacco variant. And "disposable" does not mean "risk-free": discarded Kahli bottles found in playgrounds and daycare centers pose secondary ingestion hazards to curious toddlers.

Ultimately, preventing Kahli poisonings is about respecting developmental realities. A 2-year-old cannot read warnings. A 3-year-old cannot understand "just this once." A 4-year-old’s motor skills exceed their judgment. Our environment must compensate — with engineering, education, and enforcement aligned toward one goal: zero pediatric exposures.